Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325292 · ClinicalTrials.gov registry record · Phase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
A Phase 3 study of Multiple Sclerosis, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 10
- Study locations
NCT07325292 is a Phase 3 study of Multiple Sclerosis that is actively recruiting participants, run by Sanofi. The registered enrollment target is 160 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (73% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT07325292, a Phase 3 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: The study intervention duration will be 48 weeks (12 months) for Parts A and B combined. Optional Part C will last until the initiation of a long term safety study for Frexalimab.The follow up duration after the end of study intervention (in case of discontinuation) will be 6 months. The number of scheduled visits (Parts A and B) will be 17 or 11 for participants receiving frexalimab SC or IV, respectively, with an on-site visit frequency of every month between Week 4 and Week 24 in Part A, then every 1 to 3 months in Part B, then every 6 months in Part C. Participants discontinuing treatment before the End of Study will have an additional 3 follow-up visits.
Conditions Studied
Interventions
- DRUG Frexalimab
- DRUG MRI contrast-enhancing preparations
Study Locations (10)
Florida
- Neurology of Central Florida- Site Number : 8400147 - Altamonte Springs
- Aqualane Clinical Research- Site Number : 8400026 - Naples
- Neurology Associates of Ormond Beach- Site Number : 8400086 - Ormond Beach
Alabama
- North Central Neurology Associates- Site Number : 8401100 - Cullman
- Alabama Neurology Associates- Site Number : 8400115 - Homewood
North Carolina
- Piedmont HealthCare - Lake Norman Neurology- Site Number : 8400002 - Charlotte
- Raleigh Neurology Associates- Site Number : 8400014 - Raleigh
Arizona
- Perseverance Research Center- Site Number : 8400138 - Scottsdale
California
- Private Practice - Dr. Regina Berkovich- Site Number : 8400005 - West Hollywood
Tennessee
- Hope Neurology- Site Number : 8400019 - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07325292
The ClinicalTrials.gov registry entry for NCT07325292 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (73% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Frexalimab is the first listed.
NCT07325292 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Florida, Alabama, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07325292 about?
NCT07325292 is a clinical study titled "Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis". This is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years ...
What is the current status of trial NCT07325292?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2026-01-14. Estimated completion is 2028-11-30.
What conditions does trial NCT07325292 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT07325292?
The interventions under investigation include: Frexalimab (DRUG), MRI contrast-enhancing preparations (DRUG).
Who is sponsoring clinical trial NCT07325292?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325292 being conducted?
This trial has 10 study locations across Alabama, Arizona, California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.